The largest database of trusted experimental protocols

Architect hiv ag ab combo

Manufactured by Bio-Rad
Sourced in United States

The ARCHITECT HIV Ag/Ab Combo is a laboratory diagnostic test used to detect the presence of HIV-1 p24 antigen and antibodies to HIV-1 and HIV-2 in human serum or plasma samples. The test utilizes chemiluminescent microparticle immunoassay (CMIA) technology to provide qualitative results.

Automatically generated - may contain errors

7 protocols using architect hiv ag ab combo

1

HIV Infection Determination Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
HIV infection was determined by three assays applied to samples eluted from dry blood spots: ARCHITECT HIV Ag/Ab Combo; Multispot HIV-1/HIV-2 Bio-Rad; and Realtime HIV-1 RNA, Abbot. In cases where test data were missing at the study visit, available HIV viral load and serostatus surveillance data were used from the Chicago Health Department (n=30 baseline, n=3 wave 2, n=1 wave 3). We obtained a Release of Information from each respondent to obtain these data.
+ Open protocol
+ Expand
2

Longitudinal Social Network Study of YMSM

Check if the same lab product or an alternative is used in the 5 most similar protocols
Social network testing data come from uConnect, a longitudinal study of young Black men who have sex with men (YMSM) ages 16 to 29 who reside in Chicago [16, 17, 18, 19]. Data were from the baseline visit, collected June 2013‐July 2014. RDS was used for recruitment. Index cases were selected from a distribution of social spaces that YMSM occupy (both physical and virtual spaces) and identified during focus groups. Respondents were required to: self‐identify as African‐American/Black, be born male, be 16 to 29 years of age, report oral or anal sex with a male within the past 24 months, and have a primary residence in South Chicago. Respondents were given up to six vouchers to recruit social network members who met the same criteria, $60 for the baseline interview and $20 for each enrolled social network member. HIV infection was determined by three assays applied to samples eluted from dry blood spots: ARCHITECT HIV Ag/Ab Combo; Multispot HIV‐1/HIV‐2 Bio‐Rad and Realtime HIV‐1 RNA, Abbot. Costs associated with viral load testing were excluded.
The Institutional Review Board at the University of Chicago and the National Opinion Research Center at the University of Chicago approved all procedures.
+ Open protocol
+ Expand
3

HIV Diagnosis Confirmation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
All participants were tested for HIV by rapid test‐kit Immuno chromatographic assay to diagnose HIV Type 1 and Type 2 and subtype 0/CITO TEST HIV 1/2/0. Dry blood spot specimens were collected from all participants who had HIV‐positive rapid test results; these specimens were tested in Atlanta by the United States Centers for Disease Control and Prevention by two third generation HIV diagnostic ELISAs to confirm the presence of HIV antibodies (Abbott ARCHITECT HIV Ag/Ab Combo and Bio‐Rad Genscreen Ag/Ab HIV Ultra). Samples that tested reactive on both ELISAs were confirmed for HIV seropositivity using Western blot (Inno‐lia HIV‐1/2 Score, Innogenetics, Belgium).
+ Open protocol
+ Expand
4

HIV Testing with Dry Blood Spots

Check if the same lab product or an alternative is used in the 5 most similar protocols
HIV infection was determined by three assays applied to samples eluted from dry blood spot samples: ARCHITECT HIV Ag/Ab Combo; Multispot HIV-1/HIV-2 Bio-Rad; and Realtime HIV-1 RNA, Abbot. In cases where test data were missing at the study visit, available HIV viral load and serostatus surveillance data were used from the Health Department by matching on name and demographic information. We obtained a Release of Information from each respondent to obtain these data.
+ Open protocol
+ Expand
5

Determining HIV Seroconversion from Dry Blood Spots

Check if the same lab product or an alternative is used in the 5 most similar protocols
HIV infection status was determined by three assays applied to dry blood spot samples: ARCHITECT HIV Ag/Ab Combo, Multispot HIV-1/HIV-2 Bio-Rad, and Realtime HIV-1 RNA (Abbot). All samples collected included testing for HIV-1 RNA. Acute infection was documented in cases where viral load was detectable and 4th/3rd generation tests were negative. We compared HIV serostatus at each study wave using laboratory test results from the wave 1, wave 2 and wave 3 visits; participants who tested negative at the wave 1 visit and had a seropositive result or who were acutely infected at a subsequent visit were classified as seroconverters.
+ Open protocol
+ Expand
6

HIV Testing and Counseling at Checkpoint

Check if the same lab product or an alternative is used in the 5 most similar protocols
Interviews, testing, and counseling were all carried out at the Athens Checkpoint office with linkage to care at Laiko General Hospital of Athens as appropriate. All respondents were initially tested for HIV with a fingerstick, using the INSTI HIV-1/HIV-2 Rapid Antibody Test. In the case of positive tests, follow-up blood testing with Genscreen™ ULTRA HIV Ag-Ab, ARCHITECT HIV Ag/Ab Combo, and Bio-rad Western Blot testing was used to confirm serostatus. Checkpoint staff conducted pre- and post-test counseling with all respondents.
+ Open protocol
+ Expand
7

Rapid HIV Testing and Incidence Determination

Check if the same lab product or an alternative is used in the 5 most similar protocols
All participants were tested for HIV using CITO TEST HIV‐1/2/0 rapid test kit. Dry blood spot specimens were collected from all participants who had HIV‐positive rapid test results and sent for laboratory testing at the United States Centers for Disease Control and Prevention (CDC) by two third generation HIV diagnostic ELISAs to confirm the presence of HIV antibodies (Abbott ARCHITECT HIV Ag/Ab Combo (USA) and Bio‐Rad Genscreen Ag/Ab HIV Ultra (USA)). Samples that tested reactive on both ELISAs were confirmed for HIV seropositivity using Western blot (Inno‐lia HIV‐1/2 Score, Innogenetics, Belgium).
HIV‐positive specimens were tested by the Sedia LAg assay to determine if the infection had been recently acquired. Specimens with LAg ODn ≤1.5 were considered possible recent HIV‐1 infections. All specimens with ODn >1.5 were classified as long‐term infection.
All specimens with ODn ≤1.5 were tested for viral RNA using an adapted SOP for DBS on the Abbott m2000rt Real Time HIV Test. Similar to TRIP, specimens with VL ≥1000 copies/mL were considered to be confirmed recent HIV‐1 infection cases. Specimens with VL <1000 copies/mL were classified as long‐term infections.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!